Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization

Khairuddin Memon, Laura M. Kulik, Robert J. Lewandowski, Edward Wang, Jonathan Wang, Robert K. Ryu, Ryan Hickey, Michael Vouche, Talia Baker, Daniel Ganger, Vanessa L. Gates, Ali Habib, Mary F. Mulcahy, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Purpose To compare the utility of different staging systems and analyze independent predictors of survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 (90Y) radioembolization. Materials and Methods During the period 2004-2011, 428 patients with HCC were treated with 90Y radioembolization. All patients were staged prospectively by the following staging systems: Child-Turcotte-Pugh (CTP), United Network for Organ Sharing, Barcelona Clinic Liver Cancer (BCLC), Okuda classification, Cancer of the Liver Italian Program (CLIP), Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, Chinese University Prognostic Index, and Japan Integrated Staging. The ability of the staging systems to predict survival was assessed. The staging systems were compared using Cox proportional hazards regression model, linear regression, Akaike information criterion (AIC), and concordance index (C-index). Univariate and multivariate analyses were employed to assess independent predictors of survival. Results When tested independently, all staging systems exhibited significant ability to discriminate early (long survival) from advanced (worse survival) disease. CLIP provided the most accurate information in predicting survival outcomes (AIC = 2,993, C-index = 0.8503); CTP was least informative (AIC = 3,074, C-index = 0.6445). Independent predictors of survival included Eastern Cooperative Oncology Group performance status grade 0 (hazard ration [HR], 0.56; confidence interval [CI], 0.34-0.93), noninfiltrative tumors (HR, 0.62; CI, 0.44-0.89), absence of portal venous thrombosis (HR, 0.60; CI, 0.40-0.89), absence of ascites (HR, 0.56; CI, 0.40-0.76), albumin ≥ 2.8 g/dL (HR, 0.72; CI, 0.55-0.94), alkaline phosphatase ≤ 200 U/L (HR, 0.68; CI, 0.50-0.92), and α-fetoprotein ≤ 200 ng/mL (HR, 0.67; CI, 0.51-0.86). Conclusions CLIP was most accurate in predicting survival in patients with HCC. Given that not all patients receive the recommended BCLC treatment strategy, this information is relevant for clinical trial design and predicting long-term outcomes after 90Y radioembolization.

Original languageEnglish (US)
Pages (from-to)1056-1066
Number of pages11
JournalJournal of Vascular and Interventional Radiology
Issue number7
StatePublished - Jul 2014

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization'. Together they form a unique fingerprint.

Cite this